Management Team
Genomic Health´s management team has extensive experience in the biotechnology,
healthcare and genomic industries. Team members have demonstrated success in starting
genomic businesses, developing leading drugs, launching new products and building
successful organizations.
- Randy Scott, Ph.D., Executive Chairman
- Kim Popovits, President, Chief Executive Officer
- Brad Cole, Chief Operating Officer, Chief Financial Officer
- Joffre Baker, Ph.D., Chief Scientific Officer
- Steve Shak, M.D., Chief Medical Officer
- Paul Aldridge, Ph.D., Chief Information Officer
- David Logan, Executive Vice President, Worldwide Commercialization
- Kathy Hibbs, Senior Vice President, General
Counsel
- Laura Leber, Senior Vice President, Corporate Communications
- Dean Schorno, Senior Vice President, Finance
- Tricia Tomlinson, Senior Vice President, Human Resources
Randy Scott, Ph.D., Executive Chairman
"Genomic Health is more than just a business—it is our quest to make a difference
by helping friends and loved ones manage a challenging disease. The company was
founded with a focus on cancer because we believe there is an immediate opportunity to
impact the quality of care for cancer patients and their families."
"Our first diagnostic test, Oncotype DX, was developed
to improve the quality of treatment decisions for women with breast cancer. We believe
this is a significant advance and the beginning of a whole new approach to understanding
and treating cancer at the molecular level. We believe that correlating genomic
information with clinical outcomes and making that information available to individual
patients and their healthcare providers can have a profound effect on the quality
of care. That is why we conducted multiple large clinical studies with world-renowned
clinical research groups to validate Oncotype DX."
"Our passion is to combine our collective experience in the scientific and business
worlds in building a successful company, as measured by the difference we make for
cancer patients. We believe that putting the patient´s healthcare interests
first is the core strength of our business, and that nothing could be more rewarding
than knowing that we can impact clinical
decision making for cancer patients."
Randy Scott, Ph.D. has served as Executive Chairman since January 2009. Prior to
serving as Chairman, Randy served as Chairman and Chief Executive Officer from August
2000 through January 2009. Randy was a founder of Incyte Corporation, a genomic
information company, and served Incyte in various roles, including Chairman of the
Board from August 2000 to December 2001, President from January 1997 to August 2000
and Chief Scientific Officer from March 1995 to August 2000. Randy holds a Bachelor
of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry
from the University of Kansas.
Top
Kim Popovits, President, Chief Executive Officer
"Like many of my colleagues, it is my personal experience with cancer that drives
my passion to change the way we diagnose and treat this complex disease that touches
so many lives. As we gain greater understanding of the biology of cancer, we have
an opportunity and a responsibility to develop tools that arm both physicians and
patients with personalized genomic information to individualize the treatment of
a patient´s disease. With the advent of biologics and new targeted therapeutics,
the menu of treatment options for patients with cancer is growing. It is our mission
to develop tests that employ the biology of an individual´s specific tumor
to help physicians select appropriate treatments from this expanding menu. We are
entering an era where we have the information and means to transform "one-size-fits-all"
medicine to a world where treatment is truly personalized. We remain steadfast in
our mission to provide cancer patients with access to information that
can empower them to better manage their disease. Oncotype DX is the beginning.
Our commitment is to set no limit on the end."
Kim Popovits has served as President and Chief Executive Officer since January 2009
and as President and Chief Operating Officer since January 2002. From November 1987
to February 2002, Kim served in various roles at Genentech, Inc., a biotechnology
company, most recently as Senior Vice President, Marketing and Sales from February
2001 to February 2002, and as Vice President, Sales from October 1994 to February
2001. Prior to joining Genentech in November 1987, she served as Division Manager
for American Critical Care, a Division of American Hospital Supply. Kim holds a
Bachelor of Arts degree in Business from Michigan State University.
Top
Brad Cole, Chief Operating Officer, Chief Financial Officer
"Success is defined many times in life as doing something very well and sometimes
only one thing. That can be true in business as well, and we have chosen treatment
for patients with cancer as a singular focus by which to measure success. In doing
so we have the opportunity to do the right thing very well for the benefit of medicine,
patients, physicians, payers and the healthcare system overall. Having seen both
family members and friends die from cancer in recent years, I can think of no better
way to spend my day than helping others who will be faced with similar circumstances
in the future.”
Brad Cole has served as Chief Operating Officer and Chief Financial Officer since
January 2009 and as Executive Vice President, Operations and Chief Financial Officer
since January 2008. Brad served as an Executive Vice President and Chief Financial
Officer from July 2004 until December 2007. From December 1997 to May 2004, he served
in various positions at Guidant Corporation, a medical device company, most recently
as Vice President, Finance and Business Development for the Endovascular Solutions
Group from January 2001 until May 2004. He served as Vice President and General
Manager of the Vascular Surgery Business Unit from December 1998 until December
2000; and as Vice President, Finance and IT Systems for the Cardiac and Vascular
Surgery Group from December 1997 until November 1998. From July 1994 to December
1997, Brad was Vice President, Finance and Chief Financial Officer of Endovascular
Technologies, Inc., a medical device company acquired by Guidant Corporation. From
December 1988 to February 1994, he served as Vice President, Finance and Chief Financial
Officer of Applied Biosystems Incorporated, a life sciences systems company. Brad
holds a Bachelor of Science degree in Business from Biola University and an M.B.A.
from San Jose State University.
Top
Joffre Baker, Ph.D., Chief Scientific Officer
"Genomic Health was founded to take advantage of developments in three areas:
1) decades of worldwide accumulation of scientific knowledge about cancer pathology
at the cellular, molecular and genomic level
2) the continuous development of increasingly sensitive and precise laboratory technologies
for quantifying genomic information
3) the development of scientific computing technology that permits the storage and
analysis of vast amounts of genomic information
It is an exciting fact that progress in each of these three areas continues at a
rapid pace. As a result, it is clear that the era of personalized medicine for cancer
patients has not only arrived, but has a very bright future."
Joffre Baker, Ph.D. has served as Chief Scientific Officer since December 2000.
From March 1997 to October 2000, Joffre served as Vice President for Research Discovery
at Genentech, Inc. From March 1993 to October 2000, Joffre oversaw Research Discovery
at Genentech, which included the Departments of Cardiovascular Research, Oncology,
Immunology, Endocrinology and Pathology. From July 1991 to October 1993, he served
as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech,
Joffre was a faculty member in the Department of Biochemistry at the University
of Kansas. He holds a Bachelor of Science degree in Biology and Chemistry from the
University of California, San Diego and a Ph.D. in Biochemistry from the University
of Hawaii.
Top
Steve Shak, M.D., Chief Medical Officer
"We urgently need new and more effective approaches to cancer diagnosis, treatment,
and prevention.
In the 20th century, with few diagnostic tests to select the right treatment for
individual cancers, physicians treated cancer with a “one size fits all” approach.
At Genomic Health, we have developed innovative, standardized, quantitative methods
for profiling individual cancers. Cancer drugs can be (targeted) if we are able
to discover and develop diagnostic tests to identify which patients are likely to
benefit from them. We are using the same rigorous approach used in the clinical
development and validation of the Oncotype DX Breast Cancer Assay to develop tests
for other tumor types. We passionately believe that cancer molecular diagnostics
will play an indispensable role in treatment planning for all cancer patients and
will help turn cancer into a manageable, and ultimately preventable, disease. "
Steve Shak, M.D. has served as Chief Medical Officer since December 2000. From July
1996 to October 2000, Steve served in various roles in Medical Affairs at Genentech,
Inc., most recently as Senior Director and Staff Clinical Scientist. From November
1989 to July 1996, Steve served as a Director of Discovery Research at Genentech,
where he was responsible for Pulmonary Research, Immunology and Pathology. Steve
led the clinical team that gained approval for Herceptin®, a targeted
biologic treatment for breast cancer. He also initiated the cancer clinical trials
of the anti-angiogenesis agent, anti-VEGF (Avastin®). In addition,
Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved
worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining
Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New
York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry
from Amherst College and an M.D. from New York University School of Medicine, and
completed his post-doctoral training at University of California, San Francisco.
Top
Paul Aldridge, Ph.D., Chief Information Officer
"Genomic Health is at the forefront of the revolution in healthcare and personalized
medicine. We focus on delivering information, unique and critical to every patient,
into the hands of healthcare professionals and patients that will drive treatment
decisions and improve individual outcomes. The work of delivering timely, complete
and accurate information to physicians and patients is the core mission of a team
of dedicated Information Technology professionals. Everyday, we look for ways to
improve the standard of care for cancer patients worldwide."
Paul Aldridge has served as the Chief Information Officer since September 2009.
Since 2003, Paul served as Vice President, Global Information Technology at BIOGEN
IDEC, Inc. Prior to joining BIOGEN, Paul held several positions in Developmental
Research and Information Technology and served as the Director of Development Sciences
Informatics at Pfizer Global R&D from 1991 to 2003. Paul is the author of three
patents and over 40 scientific publications and presentations. He holds a Ph.D.
and an M.S. in Analytical Chemistry from the University of Washington; and, a Bachelor
of Science in Chemistry from California State University, Sacramento, and has served
in the United States Coast Guard.
Top
David Logan, Executive Vice President, Worldwide Commercialization
"When my journey at Genomic Health began very few physicians, insurance companies
and, most importantly, patients knew there was a new test that could improve the
way newly diagnosed breast cancer patients were treated. Our challenge (or as we
say in sales, opportunity) was to educate and change treatment behavior, one physician,
payor and patient at a time. So a dedicated team representing all functions of our
company set out to shift the one-size-fits-all chemotherapy treatment paradigm.
Of all the things we accomplished, I am most proud of the financial assistance and
access programs that we established allowing patients to focus on making the best
possible treatment decision without the burden of financial barriers. Today we can
truly say we have made a significant difference in how breast cancer is evaluated
and treated."
David Logan has served as Executive Vice President, Worldwide Commercialization
since February 2010. David served as Senior Vice President, Commercial, since December
2007 and as the Vice President of Sales (Managed Care, Operations and Sales) from
2003 through 2007. Prior to Genomic Health, David served in various roles at Genentech,
Inc., most recently as Vice President of Specialty Therapeutics (Sales and Marketing)
in 2002, and prior to that he held Senior Director, Director and Management positions
in Marketing/Sales, Managed Care and Sales Operations from 1987 to 2002. Prior to
joining Genentech, David held positions in sales and sales management at Pfizer
Inc. after spending four years in the United States Army. David holds Bachelor of
Arts degree in communications/marketing from the University of Alabama.
Top
Kathy Hibbs, Senior Vice President, General Counsel
"Patients are central to all we do at Genomic Health and being able to provide doctors
and patients with better and more meaningful information, which helps individualize
cancer treatment planning, serves as a powerful motivator. I am grateful to have
the opportunity to add my skills to the important mission of improving patients’
lives."
Kathy Hibbs has served as Senior Vice President and General Counsel since January
2010. From this role, Kathy is responsible for the Legal, Regulatory and Business
Development functions at Genomic Health. Ms. Hibbs brings over 20 years of legal
and management expertise to Genomic Health. Most recently, from April 2001 through
October 2009, Kathy served as a senior vice president and general counsel at Monogram
Biosciences, where she was responsible for Legal and Regulatory matters. Prior to
her tenure at Monogram, Kathy held corporate counsel positions for Multitude, Inc.,
Varian Medical Systems and First Nationwide Bank. Kathy has participated on the
U.S. President´s Councils of Advisors on Science and Technology, the American
Clinical Laboratory Association, and the Personalized Medicine Coalition. Kathy
holds Juris Doctorate from the University of California, Hastings School of Law,
and a Bachelors of Arts in Political Science, from the University of California,
Riverside.
Top
Laura Leber, Senior Vice President, Corporate Communications
"It’s thrilling to be part of a company from its early days and to witness a group
of smart, passionate people bring a vision to reality, but it is a real privilege
to be responsible for telling the world about it. The story of Oncotype DX and the
power of personalized medicine is one that has captured a lot of attention. But
it wouldn’t have received more than a passing notice if the people of Genomic Health
hadn’t insisted on scientific and clinical rigor and on world-class customer support
for physicians and patients. And it would not have happened if not for the brave
heroes -- the breast and colon cancer patients -- whose stories shape, inform and
inspire our work on a daily basis. And best of all, Genomic Health’s story has just
begun!"
Laura Leber has served as Senior Vice President, Corporate Communications since
February 2010. Laura served as Vice President, Corporate Communications since April
2008. From 2002 through 2008, Laura served as a strategic communications consultant
to Genomic Health. Prior to joining Genomic Health, Laura worked in various communications
roles at Genentech, Inc., from June 1992 until February 2001 most recently as Vice
President, Corporate Communications, where she was responsible for the company´s
worldwide communications function. Before joining Genentech, Laura was Associate
Director, Corporate Communications for Searle, a pharmaceutical company in Chicago
from 1989-1992, where she managed corporate and product public relations and global
media relations. Prior to Searle, Laura worked in various positions at Fleishman-Hillard,
Inc. in St. Louis from 1988-1989 and Hill and Knowlton, Inc. in New York City from
1986-1988, both global public relations agencies, where she specialized in pharmaceutical
and healthcare communications. Laura holds a Bachelor of Journalism degree from
the University of Missouri, Columbia.
Top
Dean Schorno, Senior Vice President, Finance
"Having been with the company from the early days in various roles at Genomic Health,
from the clinical lab to my current position, I am proud to have helped deliver
on the promise of personalized medicine in many capacities. It has been an honor
to work with the incredibly talented employees of Genomic Health, who all share
the singular focus of helping both patients and their families. The quality of our
mission, people, clinical capabilities, and state-of-the-art laboratories, make
Genomic Health a truly exceptional place to be. "
Dean Schorno served as Senior Vice President, Finance since February 2010. Dean
served as Vice President, Finance since August 2008, and as Vice President, Operations
since January 2004. As the Operations lead, Dean managed the Genomic Health Clinical
Laboratory, Materials, and Facilities groups. Prior to this role, from July 2001
through December 2003, Dean led the finance group, as a Director and then Senior
Director. Before joining Genomic Health, from 1991 through 2001, Dean headed a CPA
and consulting firm, which he founded. Dean also worked at an international accounting
firm from 1985 to 1991. Dean holds a Bachelor of Science Degree in Business Administration,
from the University of California, Berkeley, and is a Certified Public Accountant.
Top
Tricia Tomlinson, Senior Vice President, Human Resources
"Genomic Health is a company that is on the cutting edge of technology. We are trying
to do something that hasn´t been done before. Because of this, the quality
of our employees is paramount to the success of our mission. It has been important
to us at Genomic Health to set up a culture, environment, organizational systems
and processes that are beneficial to our employees. In this way, we have developed
a workforce that is one of the best in the industry—good for the company and, ultimately
and most importantly, the patients and doctors who rely on Genomic Health assays
to help them make personalized treatment decisions."
Tricia Tomlinson has served as Senior Vice President, Human Resources since November
2007. Prior to joining Genomic Health, Tricia served as Vice President of Human
Resources at Azul Systems, a provider of enterprise server appliances, where she
held worldwide responsibility for all human resources functions and activities from
October 2005 until November 2007. Before joining Azul, Tricia served as Vice President
of Human Resources at palmOne. Prior to palmOne from January 2000 until October
2004, Tricia was Vice President of Human Resources for Handspring, Inc. Tricia also
served as a senior ranking officer of the Edify Corporation where she managed all
aspects of the worldwide human resources function. She has also held executive human
resources management positions at Xerox Corporation and Synopsys, and in the early
‘80s to early ‘90s Tricia worked at Apple Computer where she helped pioneer cutting-edge
human resources programs. Tricia holds a Bachelor of Arts degree in Sociology from
Pomona College and is a graduate of the Program for Management Development at Harvard
Business School.
Top